newsfilter
← Latest News
Business Wire·

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

  • Turn Therapeutics (NASDAQ: TTRX) will host a live webcast on Tuesday, July 7, 2026, at 4:30 p.m. ET to present interim analysis findings from its adaptive Phase 2 trial of GX-03 in atopic dermatitis.
  • A press release detailing these findings & the optimized Stage 2 study design will be issued on Wednesday, July 8, 2026.
  • The interim assessment followed a detailed multi-week review of the Stage 1 dataset overseen by lead biostatistician Dr. Bruce Stouch & Executive Clinical & Regulatory Lead Dr. Stephen Hahn.
  • The webcast will be hosted by CEO Bradley Burnam & Dr. Hahn & accessible via https://edge.media-server.com/mmc/p/jix773zk or the company's investor relations website.
  • GX-03 is Turn Therapeutics' lead investigational topical candidate designed to provide biologic-level efficacy for atopic dermatitis without systemic immunosuppression.